This company recently went public with an IPO on Friday, October 23rd 2026. They issued 17,640,000 shares at $16.00 - $18.00 per share. We will continue to update data for LYCA as it becomes available. NASDAQ:LYCA Lycia Therapeutics (LYCA) Stock Price, News & Analysis $26.40 -1.33 (-4.80%) As of 10/30/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and TrendsSEC Filings About Lycia Therapeutics Stock (NASDAQ:LYCA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lycia Therapeutics alerts:Sign Up Key Stats Today's Range$25.66▼$27.5950-Day Range N/A52-Week Range$22.19▼$36.49Volume202,428 shsAverage Volume857,210 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lycia Therapeutics, Inc. is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation. Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes. The company is applying its platform to potential treatments in areas such as autoimmune and inflammatory diseases and cancer. Lycia Therapeutics was founded in 2019 and is headquartered in the San Francisco Bay Area. The company has advanced its LYTAC platform through preclinical research and development activities, although detailed information about its commercial products and geographic operations remains limited. Its shares trade on the Nasdaq under the symbol LYCA.AI Generated. May Contain Errors. Read More Receive LYCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lycia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYCA Stock News HeadlinesLycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Buys 1,000 Shares of Stock3 hours ago | insidertrades.comLycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Acquires 52,939 SharesOctober 29 at 4:09 AM | americanbankingnews.comLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gold, and other assets. The hour long session answers the question every investor faces: when to buy, when to sell, or when to simply hold steady. Sessions run every day, including evenings and early mornings, so there's a slot that fits any schedule.October 31 at 1:00 AM | The Cycle Code (Ad)Lycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Acquires 1,952,705 SharesOctober 29 at 4:09 AM | americanbankingnews.comLycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Purchases 39,796 SharesOctober 29 at 4:08 AM | americanbankingnews.comLycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Buys 39,796 Shares of StockOctober 28 at 4:37 AM | insidertrades.comLycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesOctober 26, 2026 | globenewswire.comSee More Headlines LYCA Stock Analysis - Frequently Asked Questions How have LYCA shares performed this year? Lycia Therapeutics' stock was trading at $30.00 on October 23, 2026. Since then, LYCA stock has decreased by 12.0% and is now trading at $26.40. When did Lycia Therapeutics IPO? Lycia Therapeutics (LYCA) raised $300 million in an initial public offering on Friday, October 23rd 2026. The company issued 17,640,000 shares at a price of $16.00-$18.00 per share. Jefferies, TD Securities, Evercore ISI, Guggenheim Securities and LifeSci Capital acted as the underwriters for the IPO. When does the company's quiet period expire? Lycia Therapeutics's quiet period expires on Wednesday, December 2nd. Lycia Therapeutics had issued 17,640,000 shares in its initial public offering on October 23rd. The total size of the offering was $317,520,000 based on an initial share price of $18.00. During the company's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Lycia Therapeutics? Shares of LYCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:LYCA CIK1806540 Weblyciatx.com Phone(650) 392-3357FaxN/AEmployees65Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares55,030,000Free FloatN/AMarket Cap$1.45 billion OptionableN/A BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LYCA) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lycia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lycia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
